Aeterna Zentaris, a specialty biopharmaceutical firm, is making strides in the development and commercialization of therapeutics and diagnostic tests. The company's flagship product is Macrilen, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by attaching to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company is currently conducting preclinical trials for AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide intended for the treatment of hypoparathyroidism in adults. Aeterna Zentaris holds a license agreement with the University of Wuerzburg for the research, development, manufacture, and sale of a potential COVID-19 vaccine. The company is also developing a treatment for neuromyelitis optica spectrum disorder and is exploring potential treatments for Parkinson's disease through preclinical development. The company has secured several license and distribution agreements, including those with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea, Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries, and The University of Sheffield in the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris was founded in 1990, and its headquarters are located in Summerville, South Carolina.